High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era

References

• Fisher RI LeBlanc M Press OW, . New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
   PubMed Web of Science ®Google Scholar
• Swenson WT Wooldridge JE Lynch CF, . Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019–5026.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ Gill KK Chhanabhai M, . Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165–5169.
   PubMed Web of Science ®Google Scholar
• Bastion YSebban C Berger F, . Incidence, predictive factors and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587–1594.
   PubMed Web of Science ®Google Scholar
• Montoto S Davies AJ Matthews J, . Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426–2433.
   PubMed Web of Science ®Google Scholar
• Bernstein SH Burack WR. The incidence natural history biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009:532–541.
   PubMedGoogle Scholar
• Coiffier BLepage EBriere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM Weller EA Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Hiddemann W Kneba M Dreyling M, . Frontline therapy with rituximab added to the combination of cyclophosphamide doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ Savage KJ Gill KK, . Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood 2007;110(Suppl. 1): Abstract 790.
   Google Scholar
• Phillips GL Bernstein SH Liesveld JL, . A phase I trial: dose escalation of melphalan in the “BEAM” regimen using amifostine cytoprotection. Biol Blood Marrow Transplant 2011;17:1033–1042.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology version 2.2011. Fort Washington PA: National Comprehensive Cancer Network; 2011.
   Google Scholar
• Chen CI Crump M Tsang R, . Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001;113:202–208.
   PubMed Web of Science ®Google Scholar
• Foran JM Apostolidis J Papamichael D, . High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998;9:865–869.
   PubMed Web of Science ®Google Scholar
• Friedberg JW Neuberg D Gribben JG, . Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999;5:262–268.
   PubMedGoogle Scholar
• Ramadan KM Connors JM Al-Tourah A, . Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed lymphoma. Blood 2008;112(Suppl. 1): Abstract 4459.
   Google Scholar
• Sabloff M Atkins HL Bence-Bruckler I, . A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007;13:956–964.
   PubMed Web of Science ®Google Scholar
• Williams CD Harrison CN Lister TA, . High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001;19:727–735.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma. Haematologica 2006;91:1453–1455.
   PubMed Web of Science ®Google Scholar
• Friedberg JW Neuberg D Stone RM, . Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3128–3135.
   PubMed Web of Science ®Google Scholar
• Smith SD Bolwell BJ Advani AS, . High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. Leuk Lymphoma 2009;50:1625–1631.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C Glass B Mounier N Singh Gill D Linch DC Trneny M Bosly A Ketterer N Shpilberg O Hagberg H Ma D Briere J Moskowitz CH Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184–90.
   PubMed Web of Science ®Google Scholar
• Tan D Rosenberg SA Levy R, . Survival in follicular lymphoma: the Stanford experience 1960-2003. Blood 2007;110(Suppl. 1): Abstract 3428.
   Google Scholar
• Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005:329–334.
   PubMedGoogle Scholar
• Eide MB Lauritzsen GF Kvalheim G, . High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 2011;152:600–610.
   PubMed Web of Science ®Google Scholar
• Schaefer-Cutillo J Friedberg JW Fisher RI. Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park) 2007;21:203–212; discussion 214, 217, 221.
   PubMed Web of Science ®Google Scholar
• Gopal AK Rajendran JG Gooley TA, . High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults >or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25:1396–1402.
   PubMed Web of Science ®Google Scholar
• Gopal AK Rajendran JG Petersdorf SH, . High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002;99:3158–3162.
   PubMed Web of Science ®Google Scholar
• Clavert A Le Gouill S Brissot E, . Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2010;51:1502–1508.
   PubMed Web of Science ®Google Scholar
• Rezvani AR Storer B Maris M, . Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008;26:211–217.
   PubMed Web of Science ®Google Scholar
• Ritchie DS. Is allogeneic stem cell transplantation for transformed follicular lymphoma anti-lymphoma stem cell therapy? Leuk Lymphoma 2008;49:1852–1853.
   PubMed Web of Science ®Google Scholar
• Ramadan KM Connors JM Al-Tourah AJ, . Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 2008;42:601–608.
   PubMed Web of Science ®Google Scholar
• Villa D Savage K Crump M, . Autologous and allogeneic stem cell transplantation for transformed indolent non-hodgkin lymphoma: a report of the Candian Blood and Marrow Transplant Group (CBMTG). Ann Oncol 2011;22(Suppl. 5):1–144. [Abstract].
   Google Scholar